$ZEOX
Zeo ScientifiX, Inc. Stock $zeox

$zeox Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000182912623001524 Filed on February 14, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$1.070M	$1.443M	$6.491M
YoY Change	-33.08%	-13.36%	15.96%
Cost Of Revenue	$104.3K	$269.3K	$753.5K
YoY Change	-30.05%	150.82%	37.54%
Gross Profit	$965.9K	$1.174M	$5.737M
YoY Change	-33.39%	-24.67%	13.62%
Gross Profit Margin	90.25%	81.35%	88.39%
Selling, General & Admin	$3.142M	$4.355M	$14.58M
YoY Change	1.64%	73.43%	-18.06%
% of Gross Profit	325.31%	370.89%	254.13%
Research & Development	$194.7K		$791.3K
YoY Change	-29.53%		-29.35%
% of Gross Profit	20.16%		13.79%
Depreciation & Amortization	$155.8K	$262.8K	$332.5K
YoY Change	999.51%	1685.33%	530.94%
% of Gross Profit	16.13%	22.38%	5.8%
Operating Expenses	$194.7K	$4.355M	$791.3K
YoY Change	-93.7%	73.43%	-95.55%
Operating Profit	-$2.176M	-$3.181M	-$8.843M
YoY Change	32.59%	233.99%	-30.61%
Interest Expense	$60.97K	-$75.07K	$398.3K
YoY Change	-251.28%	1120.65%	-1149.99%
% of Operating Profit
Other Income/Expense, Net	-$49.39K	$236.6K	$249.5K
YoY Change	311.58%	62157.89%	879.22%
Pretax Income	-$2.287M	-$3.019M	-$8.897M
YoY Change	35.01%	215.12%	-30.26%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$2.287M	-$3.019M	-$8.897M
YoY Change	35.01%	215.12%	-30.26%
Net Earnings / Revenue	-213.66%	-209.17%	-137.06%
Basic Earnings Per Share	-$0.33		-$1.56
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	1.464B shares		5.688M shares
Diluted Shares Outstanding	7.010M shares		5.688M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.423M	$3.753M	$3.753M
YoY Change	846.31%	3356.85%	3356.85%
Cash & Equivalents	$1.423M	$3.753M
Short-Term Investments
Other Short-Term Assets	$714.7K	$173.2K	$173.2K
YoY Change	461.72%	148.6%	148.6%
Inventory	$281.3K	$248.5K	$248.5K
Prepaid Expenses	$214.7K	$173.2K
Receivables	$106.9K	$55.11K	$184.1K
Other Receivables	$8.000K	$7.433K	$7.430K
Total Short-Term Assets	$2.652M	$4.366M	$4.366M
YoY Change	384.06%	744.22%	744.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.544M	$1.684M	$1.795M
YoY Change	4.25%	23.06%	31.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$30.40K	$39.94K	$39.94K
YoY Change	-39.54%	-16.23%	-16.23%
Total Long-Term Assets	$1.665M	$1.834M	$1.834M
YoY Change	8.77%	29.57%	29.57%
TOTAL ASSETS
Total Short-Term Assets	$2.652M	$4.366M	$4.366M
Total Long-Term Assets	$1.665M	$1.834M	$1.834M
Total Assets	$4.318M	$6.201M	$6.201M
YoY Change	107.67%	220.79%	220.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.268M	$2.379M	$2.379M
YoY Change	15.91%	26.99%	26.99%
Accrued Expenses	$83.97K	$82.41K	$82.41K
YoY Change	-95.46%	-95.02%	-95.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$563.1K	$563.1K
YoY Change	-100.0%	279.48%	279.48%
Long-Term Debt Due		$563.1K	$143.8K
YoY Change		510.29%	55.79%
Total Short-Term Liabilities	$3.426M	$4.063M	$4.063M
YoY Change	-30.77%	-1.53%	-1.53%
LONG-TERM LIABILITIES
Long-Term Debt	$207.8K	$220.3K	$220.3K
YoY Change	-32.83%	-33.58%	-33.58%
Other Long-Term Liabilities	$7.190K	$28.59K	$28.59K
YoY Change	-93.37%	-79.64%	-79.64%
Total Long-Term Liabilities	$215.0K	$248.9K	$248.9K
YoY Change	-48.54%	-47.28%	-47.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.426M	$4.063M	$4.063M
Total Long-Term Liabilities	$215.0K	$248.9K	$248.9K
Total Liabilities	$3.641M	$4.312M	$4.312M
YoY Change	-32.16%	-6.23%	-6.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$52.81M	-$50.52M
YoY Change		21.37%
Common Stock	$1.489M	$1.479M
YoY Change		30.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$677.0K	$1.889M	$1.889M
YoY Change
Total Liabilities & Shareholders Equity	$4.318M	$6.201M	$6.201M
YoY Change	107.67%	220.79%	220.79%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.287M	-$3.019M	-$8.897M
YoY Change	35.01%	215.12%	-30.26%
Depreciation, Depletion And Amortization	$155.8K	$262.8K	$332.5K
YoY Change	999.51%	1685.33%	530.94%
Cash From Operating Activities	-$1.283M	-$1.758M	-$3.166M
YoY Change	129.06%	260.05%	21.34%
INVESTING ACTIVITIES
Capital Expenditures	$16.12K	$308.2K	$824.7K
YoY Change	-110.39%	-213.65%	-266.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$16.12K	-$308.2K	-$824.7K
YoY Change	-89.61%	13.65%	66.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.270M
YoY Change			168.54%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.032M	5.744M	$7.635M
YoY Change	-236.32%	585.45%	191.1%
NET CHANGE
Cash From Operating Activities	-$1.283M	-1.758M	-$3.166M
Cash From Investing Activities	-$16.12K	-308.2K	-$824.7K
Cash From Financing Activities	-$1.032M	5.744M	$7.635M
Net Change In Cash	-$2.331M	3.678M	$3.645M
YoY Change	-5680.93%	4575.77%	-855.77%
FREE CASH FLOW
Cash From Operating Activities	-$1.283M	-$1.758M	-$3.166M
Capital Expenditures	$16.12K	$308.2K	$824.7K
Free Cash Flow	-$1.299M	-$2.066M	-$3.991M
YoY Change	220.81%	852.17%	88.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	OCEL	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation		usd
CY2021	OCEL	Gain From Writeoff Of Liabilities Attributable To Discontinued Operations GainFromWriteoffOfLiabilitiesAttributableToDiscontinuedOperations		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	OCEL	Amortization Of Oid And Commitment Fee Discount Promissory Note AmortizationOfOidAndCommitmentFeeDiscountPromissoryNote		usd
CY2021	OCEL	Reserve For Bad Debt ReserveForBadDebt		usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2021	OCEL	Stocks Issued In Settlement Of Litigation StocksIssuedInSettlementOfLitigation		usd
CY2021	OCEL	Executive Forgiveness Of Employment Obligation In Connections With Restructuring ExecutiveForgivenessOfEmploymentObligationInConnectionsWithRestructuring		usd
CY2021	OCEL	Warrants Issued To Executives As Payment For Outstandings Compensation WarrantsIssuedToExecutivesAsPaymentForOutstandingsCompensation		usd
CY2021	OCEL	Stock Issued In Exchange For Accounts Payable StockIssuedInExchangeForAccountsPayable		usd
CY2021	OCEL	Oid Discount On Proceeds Received From Promissory Note OidDiscountOnProceedsReceivedFromPromissoryNote		usd
CY2021	OCEL	Stock Purchased From Payments Due On Accounts Payable StockPurchasedFromPaymentsDueOnAccountsPayable		usd
CY2021	OCEL	Common Stock Issued As Commitment Fee For Promissory Note CommonStockIssuedAsCommitmentFeeForPromissoryNote		usd
CY2021	OCEL	Commitment Fee Shortfall Obligation CommitmentFeeShortfallObligation		usd
CY2022	OCEL	Exchange Of Accounts Payable For Common Stock ExchangeOfAccountsPayableForCommonStock		usd
CY2022	OCEL	Stock Issued For Future Services StockIssuedForFutureServices		usd
CY2022	OCEL	Finance Lease Obligations FinanceLeaseObligations		usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001557376
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent		usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		usd
CY2022Q4	OCEL	Accrued Liabilities To Management AccruedLiabilitiesToManagement		usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2021Q4	OCEL	Promissory Note Net Of Debt Discount PromissoryNoteNetOfDebtDiscount		usd
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation		usd
CY2021Q4	OCEL	Commitment To Repurchase Shares In Connection With Settlement Of Litigation CommitmentToRepurchaseSharesInConnectionWithSettlementOfLitigation		usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	OCEL	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeiture In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitureInPeriod		shares
CY2022	OCEL	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2021	OCEL	Gain From Writeoffs And Settlements Of Accounts Payable And Notes Payable GainFromWriteoffsAndSettlementsOfAccountsPayableAndNotesPayable		usd
CY2021	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties		usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2021	OCEL	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation		usd
CY2021	OCEL	Gain From Writeoff Of Liabilities Attributable To Discontinued Operations GainFromWriteoffOfLiabilitiesAttributableToDiscontinuedOperations		usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	OCEL	Capital Contributed By Executive CapitalContributedByExecutive		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	OCEL	Commitment To Repurchase Share In Connections With Settlement Of Litigation CommitmentToRepurchaseShareInConnectionsWithSettlementOfLitigation		usd
CY2021	OCEL	Promissory Note Issued For Past Due Professional Fees PromissoryNoteIssuedForPastDueProfessionalFees		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	OCEL	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeiture In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitureInPeriod		shares
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	OCEL	Stockbased Compensation StockbasedCompensation		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses		usd
CY2021	OCEL	Executive Forgiveness Of Employment Obligations In Connections With Restructuring ExecutiveForgivenessOfEmploymentObligationsInConnectionsWithRestructuring		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021	OCEL	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-10-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--10-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55008
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	143748	usd
CY2022	dei	Entity Registrant Name EntityRegistrantName	ORGANICELL REGENERATIVE MEDICINE, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4180540
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3321 College Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 246
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Davie
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33314
CY2022	dei	City Area Code CityAreaCode	(888)
CY2022	dei	Local Phone Number LocalPhoneNumber	963-7881
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	11960956	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1463957717	shares
CY2022	dei	Auditor Name AuditorName	Marcum
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Location AuditorLocation	Fort Lauderdale, FL
CY2022Q4	us-gaap	Cash Cash	3753097	usd
CY2021Q4	us-gaap	Cash Cash	108570	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55110	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	104150	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	128939	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	7433	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	173152	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	69647	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	248510	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	234827	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4366241	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	517194	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1683516	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113416	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	110995	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	254665	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	39936	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	47682	usd
CY2022Q4	us-gaap	Assets Assets	6200688	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	92270	usd
CY2021Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	220897	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	82407	usd
CY2021Q4	us-gaap	Assets Assets	1932957	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2378531	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1873022	usd
CY2021Q4	OCEL	Accrued Liabilities To Management AccruedLiabilitiesToManagement	1542130	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4392	usd
CY2022Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	220897	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	114231	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	9575	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	144000	usd
CY2022Q4	OCEL	Promissory Note Net Of Debt Discount PromissoryNoteNetOfDebtDiscount	563111	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	174462	usd
CY2022Q4	OCEL	Commitment To Repurchase Shares In Connection With Settlement Of Litigation CommitmentToRepurchaseSharesInConnectionWithSettlementOfLitigation	500000	usd
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	125851	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4063156	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4126368	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	220340	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	331748	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28588	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	140434	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4312084	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4598550	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1479126390	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1479126390	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1132361005	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1132361005	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1479126	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1132361	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50930784	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	37826795	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50521306	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41624749	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1888604	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2665593	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6200688	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1932957	usd
CY2022	us-gaap	Revenues Revenues	6491008	usd
CY2021	us-gaap	Revenues Revenues	5597487	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	753534	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	547881	usd
CY2022	us-gaap	Gross Profit GrossProfit	5737474	usd
CY2021	us-gaap	Gross Profit GrossProfit	5049606	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14580434	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17793709	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8842960	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-12744103	usd
CY2022	us-gaap	Interest Expense InterestExpense	398260	usd
CY2021	us-gaap	Interest Expense InterestExpense	37934	usd
CY2022	OCEL	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation	30692	usd
CY2022	OCEL	Gain From Writeoff Of Liabilities Attributable To Discontinued Operations GainFromWriteoffOfLiabilitiesAttributableToDiscontinuedOperations	125851	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	249504	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25477	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8896557	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12756560	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8896557	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12756560	usd
CY2022	OCEL	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.01
CY2021	OCEL	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.01
CY2022	OCEL	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	1137645970	shares
CY2021	OCEL	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	1059488329	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1391816	usd
CY2021	OCEL	Sale Of Common Stock Value SaleOfCommonStockValue	2707270	usd
CY2021	OCEL	Exchange Of Accounts Payable For Stock ExchangeOfAccountsPayableForStock	113206	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8652307	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12756560	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2665593	usd
CY2022	OCEL	Sale Of Common Stock Value SaleOfCommonStockValue	7290000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3916590	usd
CY2022	OCEL	Capital Contributed By Executives CapitalContributedByExecutives	250000	usd
CY2022	OCEL	Warrants Issued To Executives As Payment For Outstanding Compensation WarrantsIssuedToExecutivesAsPaymentForOutstandingCompensation	649740	usd
CY2022	OCEL	Executive Forgiveness Of Employment Obligations In Connection With Restructuring ExecutiveForgivenessOfEmploymentObligationsInConnectionWithRestructuring	1526893	usd
CY2022	OCEL	Commitment To Repurchase Shares In Connections With Settlement Of Litigation CommitmentToRepurchaseSharesInConnectionsWithSettlementOfLitigation	-500000	usd
CY2022	OCEL	Common Stock Issued As Commitments Fee For Promissory Note CommonStockIssuedAsCommitmentsFeeForPromissoryNote	156231	usd
CY2022	OCEL	Exchange Of Accounts Payable For Stock ExchangeOfAccountsPayableForStock	117500	usd
CY2022	OCEL	Stock Issued In Settlement Of Litigation StockIssuedInSettlementOfLitigation	-43800	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8896557	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1888604	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8896557	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12756560	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	332508	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52702	usd
CY2022	OCEL	Amortization Of Oid And Commitment Fee Discount Promissory Note AmortizationOfOidAndCommitmentFeeDiscountPromissoryNote	323111	usd
CY2022	OCEL	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation	30692	usd
CY2022	OCEL	Gain From Writeoff Of Liabilities Attributable To Discontinued Operations GainFromWriteoffOfLiabilitiesAttributableToDiscontinuedOperations	125851	usd
CY2022	OCEL	Gain From Writeoffs And Settlements Of Accounts Payable And Notes Payable GainFromWriteoffsAndSettlementsOfAccountsPayableAndNotesPayable	249504	usd
CY2022	OCEL	Reserve For Bad Debt ReserveForBadDebt	27500	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	37455	usd
CY2022	OCEL	Stocks Issued In Settlement Of Litigation StocksIssuedInSettlementOfLitigation	-43800	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3916590	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8652307	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-17148	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	74765	usd
CY2022	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	128939	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7433	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	103505	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-19143	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51138	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	88016	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1035609	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1149307	usd
CY2022	OCEL	Increase Decrease In Accrued Liabilities To Management IncreaseDecreaseInAccruedLiabilitiesToManagement	657003	usd
CY2021	OCEL	Increase Decrease In Accrued Liabilities To Management IncreaseDecreaseInAccruedLiabilitiesToManagement	385835	usd
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-14754	usd
CY2021	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-29882	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9575	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9575	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3165840	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2680354	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	824743	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	424742	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-824743	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-424742	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	540000	usd
CY2022	OCEL	Capital Contributed By Executive CapitalContributedByExecutive	250000	usd
CY2022	OCEL	Payments On Finance Lease PaymentsOnFinanceLease	59930	usd
CY2021	OCEL	Payments On Finance Lease PaymentsOnFinanceLease	50844	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	364960	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	33557	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7270000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2707270	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7635110	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2622869	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3644527	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-482227	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108570	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	590797	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3753097	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108570	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	78625	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	28473	usd
CY2022	OCEL	Executive Forgiveness Of Employment Obligation In Connections With Restructuring ExecutiveForgivenessOfEmploymentObligationInConnectionsWithRestructuring	1526893	usd
CY2022	OCEL	Warrants Issued To Executives As Payment For Outstandings Compensation WarrantsIssuedToExecutivesAsPaymentForOutstandingsCompensation	649740	usd
CY2022	OCEL	Stock Issued In Exchange For Accounts Payable StockIssuedInExchangeForAccountsPayable	117500	usd
CY2022	OCEL	Oid Discount On Proceeds Received From Promissory Note OidDiscountOnProceedsReceivedFromPromissoryNote	60000	usd
CY2022	OCEL	Stock Purchased From Payments Due On Accounts Payable StockPurchasedFromPaymentsDueOnAccountsPayable	20000	usd
CY2022	OCEL	Common Stock Issued As Commitment Fee For Promissory Note CommonStockIssuedAsCommitmentFeeForPromissoryNote	156231	usd
CY2022	OCEL	Commitment Fee Shortfall Obligation CommitmentFeeShortfallObligation	143769	usd
CY2022	OCEL	Commitment To Repurchase Share In Connections With Settlement Of Litigation CommitmentToRepurchaseShareInConnectionsWithSettlementOfLitigation	-500000	usd
CY2022	OCEL	Promissory Note Issued For Past Due Professional Fees PromissoryNoteIssuedForPastDueProfessionalFees	256000	usd
CY2022	OCEL	Purchase Of Fixed Assets Included In Accounts Payable PurchaseOfFixedAssetsIncludedInAccountsPayable	77865	usd
CY2021	OCEL	Purchase Of Fixed Assets Included In Accounts Payable PurchaseOfFixedAssetsIncludedInAccountsPayable	71269	usd
CY2021	OCEL	Exchange Of Accounts Payable For Common Stock ExchangeOfAccountsPayableForCommonStock	113206	usd
CY2021	OCEL	Stock Issued For Future Services StockIssuedForFutureServices	10000	usd
CY2021	OCEL	Finance Lease Obligations FinanceLeaseObligations	304873	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	235313	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_805_eus-gaap--NatureOfOperations_zAtTyibwSHs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_824_zZzMwrFbk6qb">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organicell Regenerative Medicine, Inc. f/k/a Biotech Products Services and Research, Inc. (“Organicell” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Our proprietary products are principally used in the health care industry administered through doctors and clinics (collectively, “Providers”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2018, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the Company’s name from Biotech Products Services and Research, Inc. to Organicell Regenerative Medicine, Inc., effective June 20, 2018 (the “Name Change”) and during November 2021 the Name Change was effectuated in the marketplace by the Financial Industry Regulatory Agency.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended October 31, 2022 and 2021, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation and wholly owned subsidiary, which was formed to sell the Company’s therapeutic products to Providers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s leading product, Zofin™ (also known as Organicell<sup>TM</sup> Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, the Company announced that it was launching a service platform for its first autologous product called Patient Pure X<sup>TM </sup>(PPX<sup>TM</sup>). PPX<sup>TM</sup> is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood. The Company began to accept minimal orders for this service in October 2021 and to date revenues from PPX<sup>TM </sup>continue to be immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2020, the Company formed Livin’ Again Inc., a wholly owned subsidiary, for the purpose of among other things, providing independent education, advertising and marketing services, to Providers that provide medical and other healthcare, anti-aging and regenerative services. Due to limited activity, as of October 31, 2022, the Company has abandoned any future plans to operate these services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z7ZRLkN6iGma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><i><span id="xdx_861_zVdMoP8u9hI1">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain comparative figures have been reclassified to conform to the current year financial statement presentation. <span style="background-color: white">These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Cash Flows for the year ended October 31, 2021 to reclassify certain payments for the purchase of fixed assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z7yCi3R997Hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_zMKPllW2FGza">Concentrations of Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_c20221031_pp0p0" title="FDIC limits per institutions">250,000</span> per institution. At October 31, 2022, the Company held $<span id="xdx_906_eus-gaap--CashUninsuredAmount_c20221031_pp0p0" title="Cash Balances">3,731,290</span> of cash balances in one financial institution in excess of FDIC insurance coverage limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major Customer</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year ended October 31, 2022, the Company sold a total of approximately $<span id="xdx_900_eus-gaap--Revenues_pp0p0_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorAndDistributorsCustomersMember_zP43rv62j8j5" title="Revenues">2,124,000</span> (<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorAndDistributorsCustomersMember_z4PszCEHVBp3" title="Concentration credit risk percentage">32.7</span>%) to a large distributor and the distributors customers, approximately $<span id="xdx_900_eus-gaap--Revenues_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOfAnotherDistributorMember_pp0p0" title="Revenues">1,413,700</span> (<span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOfAnotherDistributorMember_zEViSR6aifg" title="Concentration credit risk percentage">21.8</span>%) to customers of another distributor and $<span id="xdx_904_eus-gaap--Revenues_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManagementServicesOrganizationMember_pp0p0" title="Revenues">702,100</span> (<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManagementServicesOrganizationMember_zXjg4MDkKT95" title="Concentration credit risk percentage">10.8</span>%) of product to a management services organization (MSO) that provides administrative services and contracts for medical supplies for several medical practices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year ended October 31, 2021, the Company sold a total of approximately $<span id="xdx_900_eus-gaap--Revenues_pp0p0_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorAndDistributorsCustomersMember_zQcsdwIUSMEj" title="Revenues">2,140,000</span> (<span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorAndDistributorsCustomersMember_z4Vrzekyj274" title="Concentration credit risk percentage">37.6</span>%) to a large distributor and the distributors customers, approximately $<span id="xdx_902_eus-gaap--Revenues_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOfAnotherDistributorMember_pp0p0" title="Revenues">709,000</span> (<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOfAnotherDistributorMember_zqAp8zoBDyz4" title="Concentration credit risk percentage">12.5</span>%) to customers of another distributor and $<span id="xdx_906_eus-gaap--Revenues_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManagementServicesOrganizationMember_pp0p0" title="Revenues">881,600</span> (<span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManagementServicesOrganizationMember_zCX7suahg39f" title="Concentration credit risk percentage">15.7</span>%) of product to a management services organization (MSO) that provides administrative services and contracts for medical supplies for several medical practices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major Supplier</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year ended October 31, 2022, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $<span id="xdx_90D_eus-gaap--CostOfRevenue_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstSupplierMember_pp0p0" title="Cost of revenues">145,000</span> and $<span id="xdx_909_eus-gaap--CostOfRevenue_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondSupplierMember_pp0p0" title="Cost of revenues">130,000</span> or <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstSupplierMember_zSrwvFtSf4X9" title="Concentration credit risk percentage">53.0</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondSupplierMember_z8gn9ekuVAAe" title="Concentration credit risk percentage">47.0</span>%, respectively, of the total amount of tissue raw material purchased during that period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year ended October 31, 2021, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $<span id="xdx_90B_eus-gaap--CostOfRevenue_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstSupplierMember_pp0p0" title="Cost of revenues">148,600</span> and $<span id="xdx_907_eus-gaap--CostOfRevenue_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondSupplierMember_pp0p0" title="Cost of revenues">131,600</span> or <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstSupplierMember_zbxEpPQJaR5b" title="Concentration credit risk percentage">53.0</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20201101__20211031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondSupplierMember_zPeVqLqnXs0a" title="Concentration credit risk percentage">47.0</span>%, respectively, of the total amount of tissue raw material purchased during that period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s supply agreements are non-exclusive and the Company does not believe it has any exposure based on the availability of raw materials and/or products from other suppliers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3731290	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zvXqm3ZZIC87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zF7gpMDJr7y5">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	27500	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	37455	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8896557	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50521306	usd
CY2021Q4	OCEL	Incremental Salary IncrementalSalary	35684900	shares
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	791326	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1120067	usd
CY2022Q4	OCEL	Operating And Finance Lease Obligation OperatingAndFinanceLeaseObligation	15000	usd
CY2022Q4	OCEL	Working Capital WorkingCapital	303085	usd
CY2022Q3	OCEL	Letter Of Intent Description LetterOfIntentDescription	Skycrest/Greyt Group and Beyond 100 each advanced Organicell $400,000 and $300,000, respectively (a total of $700,000) as good faith deposits against the $2,000,000 (a total of $4,000,000) purchase price for the Shares.
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	85096	usd
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	92601	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	163414	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	142226	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	248510	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	234827	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2123170	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	813853	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	439654	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	107146	usd
CY2022Q4	OCEL	Total Property And Equipment Net Before Leasehold Improvements TotalPropertyAndEquipmentNetBeforeLeaseholdImprovements	1683516	usd
CY2021Q4	OCEL	Total Property And Equipment Net Before Leasehold Improvements TotalPropertyAndEquipmentNetBeforeLeaseholdImprovements	706707	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1683516	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113416	usd
CY2022	us-gaap	Depreciation Depreciation	82036	usd
CY2021	us-gaap	Depreciation Depreciation	52702	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	250472	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	139868	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	83783	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	65731	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	65731	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	32864	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	387977	usd
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	23889	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	364088	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	29670	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	38037	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	237606	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	28857	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	266463	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3590	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	262873	usd
CY2021Q4	OCEL	Aggregate Shares AggregateShares	50000000	shares
CY2022	OCEL	Rent Expenses RentExpenses	31500	usd
CY2021	OCEL	Rent Expenses RentExpenses	42000	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	36352	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	31192	usd
CY2022	OCEL	Unpaid And Accrued Compensation Description UnpaidAndAccruedCompensationDescription	Ian Bothwell waived all unpaid and accrued compensation in the amount of $1,043,478, in exchange for ten-year warrants to purchase 30,000,000 Shares at an exercise price of $0.02 per share, exercisable on a “cashless basis” and a cash payment of $50,000 at Closing. At Closing, Dr. George Shapiro terminated his consulting arrangement with the Company and waived all unpaid consulting fee obligations in the amount of $139,500 in exchange for ten-year warrants to purchase 3,150,000 Shares at an exercise price of $0.02 per share, exercisable on a “cashless basis.”
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	666780	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	504979	usd
CY2022Q4	OCEL	Lab Equipment And Supplies Payables LabEquipmentAndSuppliesPayables	477255	usd
CY2021Q4	OCEL	Lab Equipment And Supplies Payables LabEquipmentAndSuppliesPayables	117606	usd
CY2022Q4	OCEL	Clinical Trial Payables ClinicalTrialPayables	312711	usd
CY2021Q4	OCEL	Clinical Trial Payables ClinicalTrialPayables	26325	usd
CY2022Q4	OCEL	Legal Fees Payables LegalFeesPayables	328121	usd
CY2021Q4	OCEL	Legal Fees Payables LegalFeesPayables	214725	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	90993	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	259442	usd
CY2022Q4	OCEL	Accrued Irs Penalty AccruedIrsPenalty	83684	usd
CY2021Q4	OCEL	Accrued Irs Penalty AccruedIrsPenalty	83684	usd
CY2022Q4	OCEL	Accrued Commissions Payable AccruedCommissionsPayable	39675	usd
CY2021Q4	OCEL	Accrued Commissions Payable AccruedCommissionsPayable	119439	usd
CY2022Q4	OCEL	Construction Payables ConstructionPayables	5474	usd
CY2021Q4	OCEL	Construction Payables ConstructionPayables	238347	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	373838	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	308475	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2378531	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1873022	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	518500	usd
CY2022Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2022	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	300000	usd
CY2022	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	100000	usd
CY2022	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.4567	pure
CY2022Q4	OCEL	Federal Operating Loss Carryforwards FederalOperatingLossCarryforwards	14297151	usd
CY2022Q4	OCEL	State Operating Loss Carryforward Indefinitely StateOperatingLossCarryforwardIndefinitely	6554845	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	4405121	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2651809	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1079723	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-563409	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5484844	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3215218	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5484844	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3215218	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1868277	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2678878	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-386555	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-554273	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	400100	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	27070	usd
CY2022	OCEL	Stockbased Compensation StockbasedCompensation	6609802	usd
CY2022	OCEL	Executive Forgiveness Of Employment Obligations In Connections With Restructuring ExecutiveForgivenessOfEmploymentObligationsInConnectionsWithRestructuring	480109	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	249665	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-9137	usd
CY2022	OCEL	Total Income Tax Expense Benefit TotalIncomeTaxExpenseBenefit	5484844	usd
CY2021	OCEL	Total Income Tax Expense Benefit TotalIncomeTaxExpenseBenefit	-3215218	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5484844	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3215218	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	798239	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	7281332	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	480109	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	3002402	usd
CY2022Q4	OCEL	State Operating Loss Carryforwards StateOperatingLossCarryforwards	9126151	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	1512039	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	396530	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	282780	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1477	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	177	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4198648	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9556437	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	302447	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	175392	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	302447	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	175392	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3896201	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9381045	usd
CY2022	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	90000	usd
CY2011	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	20000	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	83684	usd
CY2021Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	83684	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2020Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	25000	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	240000	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	50000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1000000	shares
CY2021Q2	us-gaap	Share Price SharePrice	0.136
CY2021Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	136000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100211	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35789	usd
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	60000	shares
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000	usd
CY2021Q2	us-gaap	Share Price SharePrice	0.167
CY2021Q4	OCEL	Annual Salary AnnualSalary	180000	usd
CY2021Q4	OCEL	Increasing Annual Salary IncreasingAnnualSalary	210000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1000000	shares
CY2021Q4	us-gaap	Share Price SharePrice	0.029
CY2021Q4	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	29000	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22958	usd
CY2021Q4	OCEL	Cash Provided For Credit Facility CashProvidedForCreditFacility	10000000	usd
CY2021Q4	OCEL	Purchase Of Restricted Common Shares PurchaseOfRestrictedCommonShares	7000000	shares
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.05
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3000000	shares
CY2021Q4	us-gaap	Share Price SharePrice	0.067
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	201000	usd
CY2022Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	3076923	shares
CY2022Q2	OCEL	Lawsuit Settlement By Cash LawsuitSettlementByCash	45000	usd
CY2022Q2	OCEL	Lawsuit Settlement By Issuance Of Restricted Common Stock LawsuitSettlementByIssuanceOfRestrictedCommonStock	2000000	shares
CY2022Q2	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	43800	usd
CY2022	OCEL	Repurchase Value RepurchaseValue	500000	shares
CY2021Q2	OCEL	Commission Payables CommissionPayables	30973	usd
CY2021Q2	OCEL	Newly Issued Common Stock NewlyIssuedCommonStock	176989	shares
CY2021Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.175
CY2022	OCEL	Mcpp Shares Awarded McppSharesAwarded	342500000	shares
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	49500000	usd
CY2022	OCEL	Stockbased Compensation Expense StockbasedCompensationExpense	0	usd
CY2021	OCEL	Stockbased Compensation Expense StockbasedCompensationExpense	1336500	usd
CY2021Q4	OCEL	Plan And Share Exchange Agreement PlanAndShareExchangeAgreement	The Service Providers who executed the Exchange Agreement were issued a total of 30,300,000 shares under their respective consulting or employment agreements (the “Service Provider Shares”), and the MCPP Holders who executed the Exchange Agreement received a total of 49,500,000 shares under the MCPP, for an aggregate of 79,800,000 shares of common stock. As of the effective date of the Exchange Agreement, the Service Providers and MCPP Holders who executed the Exchange Agreement agreed to exchange their respective Service Provider Shares or the shares issued under the MCPP for newly issued shares pursuant to the 2021 Plan (on a 1:1 basis, resulting in the issuance of 79,800,000 shares of common stock under the 2021 Plan (the “Exchange Shares”). Upon completion of the Share Exchange, the 2020 Plan and the MCPP (but not Awards of unexchanged shares of our common stock) were terminated.
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	83844445	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.062
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	25900000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.034
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	9901294	shares
CY2022	OCEL	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Vested Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateVestedFairValue	0.040
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	99843151	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.057
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1111111	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.029
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	83400000	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.062
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	666666	shares
CY2021	OCEL	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Vested Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateVestedFairValue	0.029
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	83844445	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.062
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	855030	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7M
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	1093022	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P14M9D
CY2022Q2	OCEL	Salesexecutivesdescription Salesexecutivesdescription	The Sales Executives will receive compensation in the form of monthly salary of $18,000 and a quarterly override during the calendar year 2020 based on revenues earned by the Company during each quarterly period that exceed $600,000 (“Override Threshold”) beginning for the quarter ended June 30, 2020. The VP Agreements also require the Sales Executives and the Company to mutually agree on the Override Threshold for calendar years 2021 and 2022 to be eligible for the Override Threshold for those years, which has yet to be agreed to.
CY2022Q4	OCEL	Contract Research Organization Outstanding ContractResearchOrganizationOutstanding	244900	usd
CY2021	OCEL	Executive Employment Agreementsdescription ExecutiveEmploymentAgreementsdescription	there was approximately $721,000 of unpaid Original Base Salary and Incremental Salary related to the period prior to December 31, 2019 and approximately $760,000 of unpaid Original Base Salary and Incremental Salary related to the period January 1, 2020 through October 31, 2021, that could be converted in the future into approximately 35,685,000 shares of common stock (weighted average conversion price of $0.042 per share)
	OCEL	Executive Employment Agreementsdescription ExecutiveEmploymentAgreementsdescription	there was approximately $721,000 of unpaid Original Base Salary and Incremental Salary related to the period prior to December 31, 2019 and approximately $1,388,000 of unpaid Original Base Salary and Incremental Salary related to the period January 1, 2020 through July 31, 2022. In connection with the Closing, the Company and each of the Executives agreed to forego their unpaid Original Base Salary and Incremental Salary (see “Changes in Management Compensation” above).
CY2022	OCEL	Lawsuit Settlement By Cash LawsuitSettlementByCash	45000	usd
CY2022	OCEL	Lawsuit Settlement By Issuance Of Restricted Common Stock LawsuitSettlementByIssuanceOfRestrictedCommonStock	2000000	shares
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
CY2022	OCEL	Contributions Contributions	0	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
ocel-20221031_def.xml	Edgar Link	unprocessable
ocel-20221031_pre.xml	Edgar Link	unprocessable
0001829126-23-001524-index-headers.html	Edgar Link	pending
0001829126-23-001524-index.html	Edgar Link	pending
0001829126-23-001524.txt	Edgar Link	pending
0001829126-23-001524-xbrl.zip	Edgar Link	pending
ex10-63_001.jpg	Edgar Link	pending
ex10-63_002.jpg	Edgar Link	pending
ex10-63_003.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ocel-20221031.xsd	Edgar Link	pending
ocel-20221031_cal.xml	Edgar Link	unprocessable
organicell_10k.htm	Edgar Link	pending
organicell_ex10-61.htm	Edgar Link	pending
organicell_ex10-62.htm	Edgar Link	pending
organicell_ex10-63.htm	Edgar Link	pending
organicell_ex23-1.htm	Edgar Link	pending
organicell_ex31-1.htm	Edgar Link	pending
organicell_ex32-1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
ocel-20221031_lab.xml	Edgar Link	unprocessable
organicell_10k_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZEOX
Zeo ScientifiX, Inc. Stock $zeox

2023 Q1 Form 10-K Financial Statement

#000182912623001524 Filed on February 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZEOX Zeo ScientifiX, Inc. Stock $zeox

2023 Q1 Form 10-K Financial Statement

#000182912623001524 Filed on February 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZEOX
Zeo ScientifiX, Inc. Stock $zeox